Fearon, Douglas T, Janowitz, Tobias (March 2021) AMD3100/Plerixafor overcomes immune inhibition by the CXCL12-KRT19 coating on pancreatic and colorectal cancer cells. British Journal of Cancer. ISSN 0007-0920
Abstract
A recent Phase 1 clinical study of the immunological effects of inhibiting the chemokine receptor, CXCR4, in patients with pancreatic ductal adenocarcinoma or colorectal cancer suggests that stimulation of CXCR4 on immune cells suppresses the intratumoural immune reaction. Here, we discuss how CXCR4 mediates this response, and how cancer cells elicit it.
| Item Type: | Paper |
|---|---|
| Subjects: | diseases & disorders > cancer diseases & disorders diseases & disorders > neoplasms diseases & disorders > cancer > cancer types > colorectal diseases & disorders > cancer > cancer types > pancreatic cancer |
| CSHL Authors: | |
| Communities: | CSHL labs > Fearon lab CSHL labs > Janowitz lab CSHL Cancer Center Program CSHL Cancer Center Program > Cancer Genetics and Genomics Program CSHL Cancer Center Program > Cellular Communication in Cancer Program |
| SWORD Depositor: | CSHL Elements |
| Depositing User: | CSHL Elements |
| Date: | 26 March 2021 |
| Date Deposited: | 28 Apr 2021 18:35 |
| Last Modified: | 13 Feb 2024 16:44 |
| PMCID: | PMC8292464 |
| URI: | https://repository.cshl.edu/id/eprint/39944 |
Actions (login required)
 |
Administrator's edit/view item |